ACG: Fewer Overt Hepatic Encephalopathy Episodes Seen With Rifaximin
Rifaximin monotherapy reduces risk for breakthrough OHE episode and results in a lower mortality rate than lactulose monotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.